GPR 119 agonists
    3.
    发明授权
    GPR 119 agonists 失效
    GPR 119激动剂

    公开(公告)号:US08772302B2

    公开(公告)日:2014-07-08

    申请号:US13377995

    申请日:2010-06-17

    摘要: The present invention relates to novel GPR 119 agonists of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating one or both of diabetes and obesity using the compounds of the invention. The present invention is directed to G-protein coupled receptor (GPCR) agonists that are useful for the treatment of obesity, diabetes and related metabolic disorders.

    摘要翻译: 本发明涉及通式(I)的新型GPR 119激动剂,其药学上可接受的盐,药学上可接受的溶剂化物,对映异构体,立体异构体和多晶型物。 本发明还涉及制备本发明化合物的方法,含有该化合物的药物组合物以及使用本发明化合物治疗糖尿病和肥胖中的一种或两种的方法。 本发明涉及可用于治疗肥胖,糖尿病和相关代谢紊乱的G蛋白偶联受体(GPCR)激动剂。

    NOVEL GPR 119 AGONISTS
    4.
    发明申请
    NOVEL GPR 119 AGONISTS 失效
    新的GPR 119激励

    公开(公告)号:US20120122905A1

    公开(公告)日:2012-05-17

    申请号:US13377995

    申请日:2010-06-17

    摘要: The present invention relates to novel GPR 119 agonists of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating one or both of diabetes and obesity using the compounds of the invention. The present invention is directed to G-protein coupled receptor (GPCR) agonists that are useful for the treatment of obesity, diabetes and related metabolic disorders.

    摘要翻译: 本发明涉及通式(I)的新型GPR 119激动剂,其药学上可接受的盐,药学上可接受的溶剂化物,对映异构体,立体异构体和多晶型物。 本发明还涉及制备本发明化合物的方法,含有该化合物的药物组合物以及使用本发明化合物治疗糖尿病和肥胖中的一种或两种的方法。 本发明涉及可用于治疗肥胖,糖尿病和相关代谢紊乱的G蛋白偶联受体(GPCR)激动剂。

    Oxime derivatives
    5.
    发明授权
    Oxime derivatives 失效
    肟衍生物

    公开(公告)号:US08742117B2

    公开(公告)日:2014-06-03

    申请号:US13141757

    申请日:2009-12-22

    IPC分类号: C07D401/00 A61K31/505

    CPC分类号: C07D413/14

    摘要: The present invention relates to novel oxime derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

    摘要翻译: 本发明涉及通式(I)的新型肟衍生物,其互变异构形式,其立体异构体,其药学上可接受的盐,含有它们的药物组合物,其制备方法,这些化合物在医药中的用途以及涉及它们的中间体 制备。

    GPR 119 agonists
    8.
    发明授权
    GPR 119 agonists 失效
    GPR 119激动剂

    公开(公告)号:US08785463B2

    公开(公告)日:2014-07-22

    申请号:US13824552

    申请日:2011-10-05

    摘要: The present invention relates to novel GPR 119 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

    摘要翻译: 本发明涉及通式(I)的新型GPR 119激动剂,其互变异构形式,其立体异构体,其药学上可接受的盐,含有它们的药物组合物,其制备方法,这些化合物在医药中的用途以及涉及 他们的准备。

    NOVEL OXIME DERIVATIVES
    10.
    发明申请
    NOVEL OXIME DERIVATIVES 失效
    新型氧化衍生物

    公开(公告)号:US20120028996A1

    公开(公告)日:2012-02-02

    申请号:US13141757

    申请日:2009-12-22

    CPC分类号: C07D413/14

    摘要: The present invention relates to novel oxime derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

    摘要翻译: 本发明涉及通式(I)的新型肟衍生物,其互变异构形式,其立体异构体,其药学上可接受的盐,含有它们的药物组合物,其制备方法,这些化合物在医药中的用途以及涉及它们的中间体 制备。